Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Double Blind, Randomized, Repeat Dose Parallel Group Study of Recombinant Human Parathyroid Hormone Analog Tablets, or Placebo Tablets, Compared to Open Label Forsteo® in Postmenopausal Women With Osteoporosis

NCT01321723 is registered in ClinicalTrials.gov with Unigene Laboratories Inc. as lead sponsor.

NCT NCT01321723
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01321723 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Double Blind, Randomized, Repeat Dose Parallel Group Study of Recombinant Human Parathyroid Hormone Analog Tablets, or Placebo Tablets, Compared to Open Label Forsteo® in Postmenopausal Women With Osteoporosis
Lead sponsor
Unigene Laboratories Inc.
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2011
Completion date
October 31, 2011
Enrollment
97 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

postmenopausal osteoporosis